文献速递泌尿生殖MRUS

疑似前列腺癌患者中基于PI-RADS v2的MRI靶向穿刺时同步系统穿刺的检出率

Yield of concurrent systemic biopsy during MRI-targeted biopsy according to Prostate Imaging Reporting and Data System version 2 in patients with suspected prostate cancer.
PubMed 文献 · Eur Radiol · 2020-09-10

研究纳入285例疑似前列腺癌患者,行3-T MRI后按PI-RADS v2评分3-5分行MRI-经直肠超声融合靶向穿刺并同步标准系统穿刺。同步穿刺较单纯靶向穿刺提高临床显著癌检出率(40.0% vs 34.4%,p=0.004),PI-RADS 4-5分患者中提高6.1%(47.0% vs 40.9%,p<0.001)。

要点

  • PI-RADS v2评分3、4、5分者前列腺癌检出率分别为18.9%、45.9%、82.1%,临床显著癌分别为9.4%、32.4%、72.6%。
  • 同步系统穿刺较单纯靶向穿刺提高临床显著癌检出率5.6%(16例),差异有统计学意义(p=0.004)。
  • 9.5%(27/285)患者仅系统穿刺阳性而靶向穿刺阴性,其中12例为临床显著癌。

诊断标准与关键数值

  • PI-RADS v2评分3分:前列腺癌检出率18.9%,临床显著癌检出率9.4%。
  • PI-RADS v2评分4分:前列腺癌检出率45.9%,临床显著癌检出率32.4%。
  • PI-RADS v2评分5分:前列腺癌检出率82.1%,临床显著癌检出率72.6%。
  • 同步靶向加系统穿刺总体临床显著癌检出率40.0%,高于单纯靶向穿刺34.4%(p=0.004)和单纯系统穿刺27.7%(p<0.001)。
  • PI-RADS 4或5分患者中,同步穿刺临床显著癌检出率47.0%,较单纯靶向穿刺40.9%提高6.1%(p<0.001)。

临床应用与阅片要点

  • 靶向穿刺与系统穿刺均阳性者中,20.0%(22例)最高Gleason评分见于系统穿刺而非靶向穿刺。
  • 9.5%(27/285)患者仅系统穿刺阳性而靶向穿刺阴性,其中12例为临床显著癌。
  • 作者认为,在系统穿刺基础上加做靶向穿刺有助于充分风险分层,减少前列腺癌诊断不确定性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To investigate the yield of concurrent systemic biopsy (SB) during MRI-targeted biopsy (MRTB) as Prostate Imaging Reporting and Data System (PI-RADS) version 2 (v2) interpretations in patients with suspected prostate cancer (PCa).

METHODS: A total of 285 patients with suspected PCa underwent prebiopsy 3-T MRI, followed by MRI-transrectal ultrasound fusion targeted biopsy and concurrent standard SB for lesions with PI-RADS v2 scores 3-5. Detection rates and positive core rates of PCa and clinically significant cancer (CSC) were evaluated.

RESULTS: In concurrent MRTB and SB, PCa and CSC detection rates were 18.9% and 9.4% for PI-RADS score 3, 45.9% and 32.4% for PI-RADS score 4, and 82.1% and 72.6% for PI-RADS score 5, respectively. Overall detection rate of CSCs (40.0%) for concurrent MRTB and SB was significantly higher than that of MRTB (34.4%, p = 0.004) or SB alone (27.7%, p < 0.001): an increase of 5.6% (16 patients) compared with MRTB alone. For patients with PI-RADS score 4 or 5, the CSC detection rate of concurrent MRTB and SB was 47.0%, an increase of 6.1% when compared with MRTB (40.9%) only (p < 0.001). Of the 110 patients with both MRTB- and SB-positive findings, 22 (20.0%) had the highest Gleason score in SB compared with that in MRTB. In 9.5% (27/285) patients including 12 patients with CSCs, only SB was positive, with negative MRTB.

CONCLUSION: Concurrent SB with MRTB based on PI-RADS v2 can yield a higher CSC detection rate compared with MRTB alone in patients with suspected PCa.

KEY POINTS: • Concurrent SB with MRTB yields an increase of 5.6% CSC detection compared with MRTB alone. • Of both MRTB- and SB-positive findings, 20.0% patients have upgraded Gleason score in SB. • In 18.4% patients, only SB was positive, with negative MRTB. Adding MRTB to SB is helpful for adequate risk stratification, reducing diagnostic uncertainty of PCa.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Kim CH, Kim CK, Park JJ, et al. Yield of concurrent systemic biopsy during MRI-targeted biopsy according to Prostate Imaging Reporting and Data System version 2 in patients with suspected prostate cancer. Eur Radiol. 2020. PMID: 32910231. doi:10.1007/s00330-020-07167-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。